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Kidney transplantation is the treatment of choice for most of the patients with end-stage
renal disease (ESRD). It improves quality of life, life expectancy, and has a lower
financial burden to the healthcare system in comparison to dialysis. Every year more
and more older patients are included in the kidney transplant waitlist. Within this patient
population, transplanted subjects have better survival and quality of life as compared
to those on dialysis. It is therefore crucial to select older patients who may benefit
from renal transplantation, as well as those particularly at risk for post-transplant
complications. Sarcopenia and frailty are frequently neglected in the evaluation of kidney
transplant candidates. Both conditions are interrelated complex geriatric syndromes
that are linked to disability, aging, comorbidities, increased mortality, and graft failure
post-transplantation. Chronic kidney disease (CKD) and more importantly ESRD are
characterized by multiple metabolic complications that contribute for the development of
sarcopenia and frailty. In particular, anorexia, metabolic acidosis and chronic low-grade
inflammation are the main contributors to the development of sarcopenia, a key
component in frail transplant candidates and recipients. Both frailty and sarcopenia are
considered to be reversible. Frail patients respond well to multiprofessional interventions
that focus on the patients’ positive frailty criteria, while physical rehabilitation and
oral supplementation may improve sarcopenia. Prospective studies are still needed to
evaluate the utility of formally measuring frailty and sarcopenia in the older candidates to
renal transplantation as part of the transplant evaluation process.
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INTRODUCTION
Kidney transplantation is the treatment of choice for most of the patients with end-stage renal
disease (ESRD). In fact, it improves quality of life (1, 2), life expectancy (3–5), and has a lower
financial burden to the healthcare system in comparison to dialysis (6). The increased prevalence
of ESRD in parallel with stable or decreased organ availability has led to an increase in the
average waiting time for transplantation. In addition, every year more and more older patients
are candidates for the enrollment in the kidney transplant list (7). Although in this case patient and
graft survival are lower than those for younger recipients (7), kidney transplant guarantees, also in
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this category, a survival advantage (4, 8) and better quality of life
(9, 10) as compared to dialysis. Therefore, it is crucial to select
which older patient may benefit from renal transplantation, and
which are at high risk for post-transplant complications.
The suitability for transplantation is based on the evaluation
of the balance between the risks faced by the patient undergoing
the procedure and the risks associated with staying on dialysis.
Sarcopenia and frailty are frequently neglected in the evaluation
of kidney transplant candidates. However, these two geriatric
syndromes havemany overlapping causes and consequences with
major impact in this specific clinical setting.
As a matter of fact, sarcopenia, which is characterized by
a loss of muscle mass and function, correlates with increased
mortality and graft failure (11, 12) while frailty, a measure of
reduced functional reserve and increased vulnerability of the
organism to stressful events, is associated with an increased
incidence of delayed graft function (13), reduced tolerance to
immunosuppressive drugs such as mycophenolate mofetil (14),
increased risk of early rehospitalization (15) and mortality in
patients with kidney transplantation (16–18). In the present
review, we will thoroughly discuss the pathogenesis and
epidemiology of frailty and sarcopenia in older transplant
candidates and recipients.
FRAILTY DEFINITION AND PATHOGENESIS
Even though the concept of frailty derives from the necessity born
in the geriatric field of assessing “biological age” and predicting
outcomes in older people (14), now it is spreading across many
different clinical contexts. Older people are at increased risk
for mortality, morbidities and hospitalization (19). However,
the chronological age cannot be considered the only precise
and linear measure of the risk of frailty and sarcopenia, and
many factors are contributing to increasing the risk of these
complications. Moreover, even after taking into consideration
the different comorbidities, it is not straightforward to predict
the vulnerability to adverse outcomes in the individual
elderly subject.
From this gap of knowledge, the concept of frailty was
born. The frailty syndrome is characterized by a reduced
functional reserve, vulnerability to stressors and increased risk
for adverse clinical outcomes (20–24). The main innovation of
the frailty concept is the predictive power of developing future
complications in response to hypothetic stressors.
It has been suggested that this clinical syndrome is the
nonlinear result of multiple dysfunctional biological systems,
regardless of the individual dysfunction, chronic disease,
and chronological age progressively dysreguling the organism
homeostasis (25–33). First of all, chronological age itself
has been associated with progressive dysregulation of the
organism homeostasis. Mild proinflammatory state (i.e., as
revealed by increased IL-6, C-reactive protein [CRP], leukocyte
count, and lymphocyte activation pathways), hypercoagulation,
anemia, impaired endocrine system, micronutrient deficiencies,
neuromuscular deficits have been also associated with the
development of frailty (22, 26, 34–37). Moreover, abnormal
metabolic systems can interact with the above factors and,
increasing the risk for frailty (i.e., abnormal IGF-1, glucose
intolerance, DHEA-S and vitamin D) (38–40). Depression
and cognitive impairment are additional risk factors for the
development of the frailty syndrome (41–44).
Frailty etiology and progression has a spiraling nature
(Figure 1), depending on the total number of the dysfunctional
systems involved, rather than on the severity of each system
dysfunction (37). Therefore, the frail organism has to find a new
precarious balance among these systems that can be disrupted
easily by stressors leading to adverse outcomes. The major
obstacle to the success of such concept was the absence of a
simple, reliable and standardized method aimed at screening for
frailty (19, 46–48).
Since frail patients frequently have reduced lean body mass,
endurance, balance, strength, and walking speed, as well as low
physical activity, all of the frailty scores include measurement of
self-reported physical activity and tests for directly quantifying
physical activity and sarcopenia (37, 45, 49, 50). In particular, the
Fried phenotype score, the most well-known frailty assessment, is
based on five components of physical impairment in older adults:
weakness (measured by grip strength), slowness (measured by
walking speed), low level of physical activity in the past 2
weeks, self-reported exhaustion, and unintentional weight loss
(measured by a questionnaire) (37, 51, 52). Individuals are
considered frail if 3 or more of the listed components are
present, pre-frail if at least one of the components is present
or non-frail (zero component) (Table 1). This test is therefore
able to identify easily the presence and score the degree of
frailty, and to predict negative clinical outcomes, such as the
incidence of falls, worsening mobility, hospitalization, and death.
The robustness of the Fried score have been documented in the
large Cardiovascular Health Study (CHS), and the test has been
successfully applied to patient cohorts of Women’s Health and
Aging Studies (40).
In consideration of the relationship between chronic disease
and frailty, some authors took into consideration the presence
and severity of chronic diseases in their “Frailty Index” (19, 53–
57). This score appears more sensitive and precise to estimate
biological age, however its clinical application has been hampered
by time consumption and the lack of distinguishing frailty from
comorbidity and disability. The relationship between chronic
disease and frailty is not clear and although they often share the
same etiology and biological pathways as well as many chronic
conditions contribute to frailty, the presence of chronic disease
does not necessarily mean frailty.
Another critical component of frailty is the cognitive
impairment, and for this reason, when the Fried phenotype score
was combined with the assessment of cognitive impairment and
depression symptoms, a significant association with disability
and worsening quality of life at 12 months was observed (41–44).
Along with the development of the frailty concept, many authors
tried to combine more and more elements in order to increase
the predictive power of the score, including memory tests (58),
comorbidities and malignancies (59), anthropometric measures,
laboratory markers and caregiver reports (60). As a consequence,
in face of a minimal increased predictive power, these scores are
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FIGURE 1 | The cycle of frailty (45). The four key factors of frailty (in the central circle) are sarcopenia, lower resting metabolic rate, lower energy expenditure, and
chronic undernutrition. These factors are interconnected and amplifying the process and it is hard to distinguish the first factor that started it. In the peripheral area are
represented the contributors to these factors. The main contributors to sarcopenia are weight loss (through protein and micronutrient deficit and increased catabolism),
musculoskeletal senescence and various diseases. Sarcopenia itself, through the reduction of muscle strength and power, provokes one of the key features of the
frailty assessment: the reduced walking speed. The diaphragm and visceral muscle sarcopenia along with anemia are responsible for reduced oxygen uptake (VO2)
and subsequent exhaustion, which contribute in slowing the walking speed. Reduced walking speed is associated with lower physical activity and subsequent lower
energy expenditure. In some cases, the marked reduced walking capacity can configure a disability with loss of independency and need for assistance.
Neuroendocrine dysregulation, frequently observed in older people, can reduce the appetite (anorexia of aging) and contribute to chronic undernutrition along with the
lower energy expenditure with subsequent weight loss. A mild and chronic inflammation can have a negative impact in these processes. VO2, oxygen uptake.
applicable only by trained geriatric teams, being time consuming
in the clinical setting (61).
FRAILTY IN TRANSPLANT CANDIDATES
Thanks to the increased life expectancy and the improvement
in medical and surgical management, an increasing number of
patients with CKD (62) over 65 years are evaluated for kidney
transplant waiting list (63, 64). A number of studies have, indeed,
shown a significant improvement in the overall life expectancy
(mortality risk 40–60% lower) for older patients receiving a
kidney transplant compared to similar waiting-listed patients
remaining on dialysis (65–70), even taking into consideration the
significantly higher incidence of early mortality (65, 68, 69, 71)
and the use of extreme aged (>75 years) cadaveric donors (70).
It is therefore crucial to evaluate at the time of wait
listing evaluation which older kidney transplant candidate
will benefit from kidney transplantation, and which are
subject to an unacceptable risk of adverse events following
transplantation (64).
Frailty as defined by Fried has been proposed as a practical
and useful assessment in clinical practice evaluation for kidney
transplant waiting list (17). The prevalence of frailty is higher
among dialysis patients, and it increases with age: 44% of
dialysis patients under 40 years are frail, while this prevalence
reach 78% among dialysis patients above 70 years. In addition,
functional decline is highly prevalent in older patients during
the first 6 months of dialysis, especially in the presence of
frailty (72). Patients with CKD (62) typically present many
risk factors for frailty (71), such as anemia, osteoporosis,
cardiovascular disease and chronic inflammation (72, 73).
They also experience neuroendocrine changes, like 25-OH
vitaminD deficiency, insulin-resistance (73) and low testosterone
levels (74), commonly associated with frailty and sarcopenia
(32). Since dietary limitations are also part of the medical
prescription to CKD patients, in order to reduce the daily
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TABLE 1 | Measurement and Definition of Frailty Components using the Fried criteria (45).
Component Positive assessment (=1 point each) Methods
Shrinking • Unintentionally loss of 10 pounds or more in the last year The current weight is asked to the patient.
The previous year weight is asked to the patient or derived from
medical records.
Exhaustion • Feeling that “everything I did was an effort” OR “I could not get going”
for 3 or more days in the past week
The CES-D Questionnaire
Physical activity • Men who expended <383 Kcals/week
• Women who expended <270 Kcals/ week
The short version of the Minnesota Leisure Time Activity questionnaire is
used to assess frequency of physical activities. Physical activity is
converted to Kcals/week expended using a standardized algorithm
(number of days physical activity in the past 2 weeks × duration of activity
in minutes × Kcals burned per minute).
Walking speed • Men height≤ 173 cm that required ≥ 7 s
• Men height > 173 cm that required ≥ 6 s
• Women height ≤ 159 cm that required ≥ 7 s
• Women height > 159 cm that required ≥ 6 s
• Patients who are unable to complete the test due to
physical limitations
Patients are timed while walking 15 feet. Stratified by gender and height.
Grip strength • Men BMI ≤24 cutoff ≤29
• Men BMI 24.1–28 cutoff ≤30
• Men BMI>28 cutoff ≤32
• Women BMI ≤23 cutoff ≤17
• Women BMI 23.1–26 cutoff ≤17.3
• Women BMI 26.1–29 cutoff ≤18
• Women BMI>29 cutoff ≤21
• Patients who are unable to complete the test due to
physical limitations
Grip strength is measured using a Jamar hand-held dynamometer. The
cut-offs (kg) are gender- and BMI-specific.
Each of the 5 components was scored as 0 or 1 representing the absence or presence of that component. The aggregate frailty score was calculated as the sum of the component
scores (range 0–5). CED-D Center for Epidemiologic Studies Depression Scale; BMI, body mass index.
intake of phosphorus, potassium, salt and water, this very
fact can exacerbate malnutrition and contribute to sarcopenia
(75). Moreover, cognitive impairment is common among ESRD
patients, with a prevalence of cognitive decline in older patients
on hemodialysis between 16 and 38% (76–79).
The investigation of frailty and its effect on transplant
outcomes, could help the clinicians to inform the ESRD patients
on treatment options and tailor the pre- and post-transplant
follow up strategies (80). In fact, a prospective study of ESRD
patients on hemodialysis, has linked frailty to a 2.6-fold increase
of mortality risk (95% confidence interval, 1.04–6.49; P = 0.041).
Of note, this important risk increase has been independent of age,
sex, comorbidities, and disability (16). Also, in kidney transplant
candidates, who are generally selected among “healthier” patients
on dialysis, frailty has been significantly associated with mortality
on the transplant waiting list (hazard ratio [HR]: 6.7, confidence
interval [CI]: 1.5–30.1; P = 0.01) independently of age, diabetes,
or duration of dialysis (81).
Frail kidney transplant candidates are also less likely to be
listed for kidney transplantation compared to non-frail patients
(hazard ratio, 0.62; 95% confidence interval, 0.56–0.69; P <
0.001), independently of age and other demographic factors (82),
and they are by one third less frequently transplanted than their
non-frail counterpart (incidence rate ratio, 0.68; 95% confidence
interval, 0.58–0.81; P < 0.001) (82).
Recently it has been shown that almost 50% of candidates
experience a frailty phenotype worsening while on waiting list,
and that these changes are associated with increased risk of
mortality and longer hospitalization. Monitoring these changes
can in fact improve the post-transplant risk stratification, and
modify the suitability to kidney transplantation (83).
FRAILTY IN TRANSPLANT RECIPIENTS
Patients that are considered frail at the time of transplant have
more than 2-fold adjusted risk of mortality (95% CI: 1.01–4.65,
p= 0.047) (17) compared to non-frail patients, independently of
recipient age (13). Frailty has been also associated with a 1.94-fold
increased risk for delayed graft function within the first post-
transplant week (95%CI, 1.13–3.36; P= 0.02) (15), and increased
rate of both morbidity and hospital readmission (adjusted RR =
1.61, 95%CI: 1.18-2.19, p= 0.002) in the first month after surgery
(15). Frail kidney transplant recipients are more susceptible to
drug-related adverse events, like in the case of mycophenolate
mofetil use, with a 1.29-times (95%CI:1.01–1.66; P = 0.04) more
frequent need for dose reduction (14), being this latter effect
independently associated with a substantially increased risk of
death-censored graft loss (aHR, 5.24; 95% CI, 1.97–13.98, P =
0.001) (14). Finally, frailty has been recently associated with
medium-term cognitive decline (measured by Modified Mini-
Mental State Examination) post-kidney transplantation (84).
Despite the increasing evidence of the role of frailty in
predicting the pre- and post- transplant outcomes, no current
guidelines are indicating a threshold of frailty score at which a
patient should be excluded from the waiting list (64).
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Notably, after an initial worsening early after kidney
transplantation, adult recipients of all ages experience an
improvement of the frailty score at 3 months (85). And despite
the fact that patients that are considered frail at the moment
of transplantation, still present a higher frailty score over
time, these patients are more likely to show an improvement
after transplantation, showing the reversible state of frailty and
the advantage of transplanting this population (85). Moreover,
frail patients reported a better improvement in post-transplant
health-related quality of life compared to non-frail transplant
recipients (frail, 1.35 points/month; 95% confidence interval [CI],
0.65–2.05; non-frail, 0.34 points/month; 95%CI,−0.17–0.85; P=
0.02) (86).
Recent KDIGO guidelines suggest that patients should be
evaluated for frailty at the time of listing and while on
the waiting list, in order to better define inherent risks and
enable optimization strategies (87). Further studies are needed
to investigate the role of frailty in predicting specific post-
transplant outcomes (88) and define the phenotypes of frail
transplant candidates who are expected to benefit the most
from transplantation over dialysis, in order to tailor the clinical
approach to their unique needs and develop interventions to
reverse frailty both pre- and post- transplantation (87).
SARCOPENIA DEFINITION AND
PATHOGENESIS
Sarcopenia (from the Greek sarx = flesh, penia = scarcity) is a
complex geriatric syndrome associated with the loss of muscle
mass and reduced muscle strength (Table 2) (89). Sarcopenia
can be defined as primary or secondary. In the first case, it is
a sole consequence of aging, while secondary sarcopenia has
a multifactorial etiology, and include as possible causes the
decline in physical activity, alterations of the endocrine system,
presence of comorbidities, inflammation, insulin resistance and
nutritional inadequacy (90). However, in a clinical setting
characterized by prevalent older subjects, both age-related and
diseases related factors play a role in the development of
sarcopenia. Reduced muscle strength leads to a reduction in
muscle performance, and is a major cause of disability, mortality
and other adverse outcomes (91) (Figure 1).
The 2010 European Working Group on Sarcopenia in Older
People (92) recognized for the first time that muscle strength is
also an important component of sarcopenia. The group defined
the syndrome as a progressive loss of skeletal muscle mass and
strength, increasing the risk for the development of physical
disability, poor quality of life and death (92–98).
Despite being primarily considered a natural part of aging,
the degree of muscle loss is highly variable and depends on the
presence of some risk factors. Muscle homeostasis is maintained
thanks to a fine balance between the formation of new
myocytes, hypertrophy and protein catabolism. This equilibrium
is controlled by the nervous, endocrine and immune systems, and
is highly affected by nutrition and physical activity (99).
Lack of exercise is believed to be themost important risk factor
for the development of secondary sarcopenia (100). Muscle mass

















Cut-off points: Muscle strength: grip strength: < 27Kg for men and < 16Kg for women;
chair stand: > 15 s for five rises.
Muscle mass: Appendicular skeletal muscle mass (ASM): < 20Kg for men and < 15
Kg/women; ASM index (ASM/hight2): < 7 Kg/m2 for men and < 5.5 Kg/m2 for women.
Muscle function: Gait speed < 0.8 m/s.
picks at around 30 years of age and starts to decline in a rate of
0.5–1% every year, accelerating after 65 years of age (101, 102).
A 30% cumulative loss of muscle mass and a 20% loss in muscle
cross-sectional area until reaching 80 years have been described
(103), being the reduction in muscle fibers and strength more
pronounced in people with a sedentary lifestyle.
Hormonal imbalances, including age-related reduction in
growth-hormone (GH), testosterone, thyroid hormones, insulin-
resistance, reduced IGF-1, and increased cortisol lead to loss of
muscle mass and strength (104). Particularly, the reduction of
hormonal anabolic signals and the increase in catabolic signals
promoted by glucocorticoids and pro-inflammatory cytokines
such as TNF-α and IL-6 both contribute to the loss of muscle
mass (104).
Inflammatory cytokines activate muscle ring finger 1
(MURF1), which, like atrogin-1, activates the ubiquitin-
proteasome degradation system. In addition, they also cause
apoptosis through the activation of NF-kB, and activation of
the caspase 8. Increased concentrations of TNF-α and IL-6 have
been described in older adults (105).
In parallel to the reduced ability to synthetize muscle fibers,
a reduction in energy and protein intake is common in the
development of sarcopenia. The lack of protein to sustain muscle
mass associates with accumulation of oxidized proteins that are
scarcely removed from the muscle via the proteolytic system,
leading to an increase of non-contractile dysfunctional protein
content in the skeletal muscles. This effect is thought to explain,
at least in part, why muscle strength is severely decreased in
sarcopenia (106).
SARCOPENIA IN KIDNEY TRANSPLANT
CANDIDATES
Sarcopenia is a frequent finding in kidney transplant candidates
(107), in whom muscle loss occurs at a younger age, and more
markedly, in comparison to age-matched controls (108, 109).
This phenomenon has been associated to nutritional problems,
chronic diseases, sedentary lifestyle and drug-related side effects
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(110, 111), and its prevalence seems to be related with worsening
of renal function (112).
Currently available evidence divides the causes of sarcopenia
in kidney transplant candidates into two groups: causes related
to the kidney disease itself, and causes related to the chronic low-
grade inflammatory process typical of patients on dialysis, but
also present in earlier stages of the disease (113, 114). Factors
related to kidney disease that contribute to the development
of sarcopenia include nutritional deficits and consequent
malnutrition, vitamin D deficiency, metabolic acidosis, insulin
resistance, low physical activity, hyperparathyroidism, and
proteinuria (115).
Inadequate nutrient intake is the most important factor that
contributes to the development of sarcopenia in these patients.
Progressive loss of appetite begins already in the earlier stages
of CKD (116), and it worsens in parallel to the loss of renal
function. In this clinical setting anorexia can be viewed as
the consequence of the complex negative interactions between
metabolic signaling, accumulation of uremic toxins, alterations
of factors that regulate appetite (such as gastric mediators,
adipokines, and cytokines), and altered hypothalamic signaling
(116). In addition, CKD patients on dietary nutritional treatment
(the so called conservative treatment) usually undergo prolonged
restrictions of protein intake, as well as of phosphorus, potassium
and sodium; all of these dietetic measures, though aimed at
preventing metabolic complications, can set the stage to the
development of malnutrition, especially when energy intake is
inadequate (117, 118).
Metabolic acidosis is a very frequent complication of ESRD,
and represents a powerful stimulus for protein catabolism (119).
In fact, metabolic acidosis activates two systems responsible
for intracellular protein degradation, the caspase-3 and the
ubiquitin-proteasome systems, and may also reduce protein
synthesis and promote insulin and GH resistance, thus leading
to negative protein balance (120, 121).
Insulin resistance is one of the most important metabolic
challenges in kidney transplant candidates. It has been
demonstrated that diabetes is a major risk-factor for sarcopenia
in hemodialyzed patients, who suffers from increased protein
degradation and loss of lean body mass in comparison to
non-diabetic patients (122, 123). However, insulin resistance
can be observed also in non-diabetic patients on dialysis,
and it is associated with increased protein catabolism
also mediated by the ubiquitin-proteasome pathway (124).
Insulin resistance is also responsible for a decrease in muscle
phosphatidylinositol 3 kinase (PI3K), which may explain
the overactivation of the ubiquitin-proteasome pathway.
Beside of metabolic acidosis, vitamin D deficiency also
contributes to the development of insulin resistance by
affecting pancreatic insulin secretion (125, 126). Moreover,
muscle is also a target organ for vitamin D, increasing calcium
influx from cellular membranes and stimulating muscle
synthesis when vitamin D binds to its muscular receptor. Low
concentrations of vitamin D are associated with muscle atrophy
and sarcopenia (127).
Proteinuria as a consequence of glomerular kidney
disease could represent an important additional way of
protein loss even in the earlier stages of CKD. Chronic
inflammation is a frequent finding in ESRD patients; its
consequences include an increase in nutritional needs and the
development of anorexia through a lack of balance between
orexigenic/anorexigenic mechanisms that control the energetic
homeostasis of renal patients (128, 129). Many factors are
thought to contribute to the pathogenesis of inflammation
in ESRD: worsening of renal function by a reduction of the
elimination of pro-inflammatory cytokines and uremic toxins,
acute and chronic comorbidities, and factors related to the
dialytic treatment itself, such as membrane and dialysis fluid
bioincompatibility (130).
In fact, recent data show that the duration of hemodialysis
before transplantation is highly correlated with the presence of
sarcopenia in kidney transplant candidates (131).
Furthermore, evidence suggest a key role for the
gastrointestinal tract as a consequence of intestinal dysbiosis
and barrier disruption (132–134). The uremic milieu and
reduced intake of fibers that are characteristic of CKD/ESRD
patients are responsible for negative effects both on the
resident microbial population (i.e., dysbiosis,) and in the
structure and function of the gastrointestinal tract, enhancing
its permeability (107, 132, 134). This dysbiotic environment
of CKD/ESRD is characterized by a switch toward a more
proteolytic metabolism profile, leading to an increase in protein
fermentation (putrefaction), the generation of increased amounts
of potentially toxic compounds (i.e., ammonium, thiols, phenols,
indoles) that are absorbed into the bloodstream and accumulate
in CKD/ESRD patients (107, 134). In addition, the deranged
and more permeable intestinal barrier may facilitate bacterial
translocation, which is the passage of bacteria or their structural
component lipopolysaccharide (LPS) from the lumen to the
blood (107, 134), with a final stimulation effect leading to chronic
inflammation. Cytokines like TNFα, IL-6, IL-8, and IFN-γ are, in
fact, mentioned among the most frequently observed indicators
and activators of muscle proteolysis, while CRP seems to be a
useful and inexpensive marker of systemic inflammation, despite
being nonspecific (135).
Physical activity and function (defined as the capacity to
perform activities of daily living), which are key components in
the diagnosis of sarcopenia, are markedly reduced in transplant
candidates in comparison to age-matched controls (136, 137).
Reasons for reduced physical activity are fatigue on dialysis
days, lack of time and motivation, physical problems and pain
(138–140). In addition, some physical limitations related to the
peritoneal dialysis and the presence of central venous catheter
may play a role in limiting the enrollment in some sports. In
this clinical setting, physical inactivity represents a modifiable
risk factor for the development of sarcopenia, and it may cause
further increase in the already high cardiovascular risk of these
patients (137, 141). Physical exercise, even in dialyzed patients,
is able to reduce depressive symptoms, to improve the quality of
life, appetite and energy supply (141).
However, despite the aforementioned higher prevalence
of sarcopenia among kidney transplant candidates and
its correlation with negative post-transplant outcomes, its
evaluation is frequently neglected at the time of waiting list.
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SARCOPENIA IN KIDNEY TRANSPLANT
RECIPIENTS
The presence of sarcopenia at the time of kidney transplant
has been associated with increased mortality, graft failure, and
postoperative complications such as infections (11, 12, 142, 143).
Successful renal transplantation is able to correct or improve
many of the conditions related to CKD that promotes
muscle wasting and sarcopenia, such as metabolic acidosis
and chronic inflammation. However, the use of glucocorticoids
as immunosuppressive therapy and the improved, but still
suboptimal, renal function can continue to propitiate negative
changes in body composition of renal transplant recipients. In
general, an increase in body weight is frequently observed early
following kidney transplantation (144, 145). However, it seems
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30–35 Kcal/Kg/day
(adjusting for age and
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to be predominantly due to an increase in fat mass instead
of muscle mass (146–148). In addition, low physical activity, a
common finding in transplant recipients (149, 150), resulting
from a combination of low exercise capacity and exercise
intolerance/barriers that starts already in the pre-dialysis phases
of CKD (140, 151), may significantly contribute to the reduction
of muscle mass and function. Skeletal muscle dysfunction,
particularly reducedmuscle strength, is an important contributor
to exercise intolerance in renal transplant candidates and
recipients (151, 152). In summary, it seems that changes in body
composition of transplant recipients are mainly characterized
by an early gain in adipose tissue, while the restoration of
muscle mass and function seems to be incomplete. The excess
of fat mass and the presence of reduced muscle mass found in
transplant recipients characterize a condition called sarcopenic
obesity (153). Many studies have shown that when combined,
sarcopenia and obesity (as assessed by excess fat mass or central
obesity, but not BMI values only) may act in a complementary
way increasing the risk of mortality, disability, cardiovascular
disease, and metabolic impairment (154–158).
SARCOPENIA AND FRAILTY
Although the pathogenesis of frailty and sarcopenia is not
fully understood, these two conditions seem to share risk
factors, pathways and often contribute to the same negative
outcomes. A growing interest in the frailty and sarcopenia
definition and pathogenesis has been observed also in kidney
transplant field.
FIGURE 2 | Algorithm to identify cases of sarcopenia in transplant candidates and recipients [adapted from (89)].
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Sarcopenia is one of the most important key components
of frailty in kidney transplant candidates, and recognizes as
pathogenetic factors aging, physical inactivity, malnutrition,
acidosis, metabolic/neuroendocrine dysregulation and mild
chronic inflammation (159). Once established, sarcopenia can
produce a decrease in resting metabolic rate, contributing to the
loss of appetite and malnutrition. The skeletal muscle and the
diaphragm can become weaker, leading to increase exhaustion
(160), physical inactivity and potential disability in a loop way
process (32).
Available evidence regarding the prevalence of frailty
components in frail community dwelling adults, revealed that
reduced gait speed and weakness were the most common
positive Fried criteria (43 and 54% respectively) (41). Increased
relative risk for developing weakness and low activity was
also reported, in comparison to the risk of developing any
other frailty component during 7.5 years of follow up in
initially non-frail women (161). This finding suggests that having
frailty without sarcopenia is theoretically possible, however it is
clinically unlikely.
In the general population sarcopenia has been shown to be
twice as common as frailty (162). In kidney transplant candidates,
which are selected among the healthier dialyzed patients, the
prevalence of these two conditions almost overlaps at around
20% (17), however when the whole dialyzed population is
analyzed, the prevalence rises up to 20–44% for sarcopenia and
42% for frailty (163, 164).
Both frailty and sarcopenia are considered reversible
conditions. Epidemiological and interventional studies showed
that multiprofessional treatments based on individual’s frailty
positive criteria are successful in improving patients’ frailty
status (165–167). In addition, other studies specifically have
shown that it is possible to improve muscular components of
frailty, and consequently sarcopenia (168, 169), confirming that
frailty and sarcopenia are linked conditions that correlate to
musculoskeletal aging.
PRACTICAL CONSIDERATIONS
In order to prevent or identify subjects at risk for sarcopenia, the
EWGSOP2 recommends the use of the SARC-F questionnaire
in healthy community living older subjects (89). The SARC-
F is a self-reported 5-item questionnaire that reports patients’
perceptions and experiences regarding strength, walking ability,
chair standing, stair climbing and falls (170). Considering that the
SARC-F lacks validation in the renal setting and that sarcopenia
in renal patients is mostly secondary, with multiple factors
influencing its development, a more comprehensive screening
shall be recommended. Periodic appetite assessment tools and
food diaries are critical, and allows early intervention when
nutrient intake is already slightly reduced (<1 g/Kg/day of
protein and <30 Kcal/Kg/day in hemodialysis patients, and <0.8
g/Kg/day in transplant recipients with adequate graft function)
(115). In fact, in hemodialysis patients, an intake of protein of
<0.8 g/Kg/die and/or calories<25 Kcal/Kg/die in associated with
increased risk of malnutrition and sarcopenia (11, 128, 171).
Calculation of the protein catabolic rate (PCR) is useful to
estimate protein intake in stable patients (172). In transplant
recipients not on hemodialysis, PCR can be calculated based
on 24 h urinary urea nitrogen excretion, or by urea kinetics in
patients on dialysis (172, 173). The recommended energy and
protein intake for dialysis patients and transplant recipients are
described in Table 3. In addition, considering that patients with
ESKD frequently perform blood tests, the combined evaluation of
serum albumin and CRP might be useful to assess inflammation.
Most importantly, the treatment of conditions related to the renal
disease itself that contribute to the increase of catabolism (i.e.,
proteinuria, metabolic acidosis, hyperparathyroidism, vitamin
D deficiency, chronic inflammation) is a key component to
prevent the development of sarcopenia in renal patients (115).
On this premises, in Figure 2 an algorithm is proposed to
identify the presence of sarcopenia among transplant candidates
and recipients.
CONCLUSION
Kidney transplantation is the treatment of choice for most
of the patients with ESRD. The suitability for transplantation
is based on the evaluation of risks faced by the patient
undergoing the procedure and the risks associated with staying
on dialysis.
Frailty and sarcopenia are interrelated complex geriatric
syndromes that are linked to disability, aging and comorbidities.
CKD and ESRD are characterized by multiple factors that set the
stage for the development of sarcopenia and frailty. Despite the
available evidence showing that frailty and sarcopenia correlate
to worse outcomes in transplant recipients, both conditions
are frequently neglected in the evaluation of kidney transplant
candidates. Prospective studies are needed to evaluate the utility
of formally measuring frailty and sarcopenia as part of the
transplant evaluation process.
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